Progyny reported a record first quarter revenue of $122.1 million, a 51% increase compared to the first quarter of 2020. Net income increased by 318% to $15.2 million, or $0.15 income per diluted share. The company issued revenue guidance of $126.0 to $131.0 million for the second quarter of 2021, reflecting growth of 95% to 103%.
Revenue was $122.1 million, a 51% increase compared to Q1 2020.
Fertility benefit services revenue was $88.9 million, a 50% increase from Q1 2020.
Pharmacy benefit services revenue was $33.3 million, a 54% increase compared to Q1 2020.
Net income was $15.2 million, an increase of 318% from Q1 2020.
The company is providing the following financial guidance for the second quarter of 2021: Revenue is projected to be $126.0 million to $131.0 million, reflecting growth of 95% to 103%. Net income is projected to be $6.5 million to $8.8 million, or $0.06 to $0.09 per diluted share. Adjusted EBITDA is projected to be $17.5 million to $19.0 million.
Visualization of income flow from segment revenue to net income